Fentanyl buccal - Teva
Alternative Names: E-fen buccal tablets; Effentora; Fentanyl buccal - Cephalon; Fentanyl citrate - Teva; Fentora; OraVescent® fentanyl; OVFLatest Information Update: 05 Nov 2023
At a glance
- Originator CIMA LABS
- Developer BMP Sunstone Corporation; CIMA LABS; M. D. Anderson Cancer Center; Taiho Pharmaceutical; Teva Pharmaceutical Industries
- Class Amides; Benzene derivatives; General anaesthetics; Opioid analgesics; Piperidines; Small molecules
- Mechanism of Action Opioid mu receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Cancer pain
- Phase II Dyspnoea
- Preregistration Submission Withdrawal Pain
- Discontinued Neuropathic pain
Most Recent Events
- 04 Dec 2019 Teva Pharmaceuticals completes a phase II trial in Dyspnoea (in cancer patients) in USA (Buccal) (NCT01856114)
- 02 Aug 2019 Phase II development is still ongoing for Dyspnoea USA (NCT01856114)
- 02 Aug 2019 No development reported - Phase-II for Dyspnoea in Germany (Buccal) (EudraCT2011-005797-32)